Phase 4 N=22 Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)
MELAS Syndrome
Primary: Clinical Safety of TIV Vaccine — 4; 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=66 An Alternate Dosing Schedule for Pentavalent Rotavirus Vaccine (RotaTeq)
Diarrhea · Gastroenteritis
Primary: G1 Serum-neutralizing Antibody — 188; 184.5 titers
Phase 4 N=269 BENEFITS OF ACLIDINIUM BROMIDE IN THE RELIEF OF COPD SYMPTOMS INCLUDING COUGH
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Overall Exacerbations of Chronic Pulmonary Disease Tool-Respiratory Symptoms (E-RS) Total Score Over the 8 Week Study Period — -1.75; -0.73 Score…
Phase 4 N=21 Endoscopic Ultrasound (EUS) Guided Treatment With Humira for Crohn's Perianal Fistulas
Crohn Disease · Rectal Fistula
Primary: Number of Participants With Durable Fistula Healing — 7; 8 participants
Phase 4 N=165 Treatment for Alcoholism and Post-Traumatic Stress Disorder (Naltrexone)
Alcoholism · Alcohol Dependence · Post-Traumatic Stress Disorder
Primary: Posttraumatic Stress Disorder (PTSD) Symptom Scale - Interview (PSS-I-IV) — 27.1; 30.3; 27.7; 27.5 units on a scale
Phase 4 N=12 Study to Evaluate Effect of Nebivolol on Angina in Women With Microvascular Disease
Microvascular Angina
Primary: Seattle Angina Questionnaire Score — 83.3; 29.2; 74.1; 67.6 units on a scale
Phase 4 N=128 The Laparotomy Study
Gastrointestinal Cancer
Primary: Surgical Rating Score — 4; 4.75 units on a scale — p=<0.05
Phase 4 N=15 Effect of Prolonged PDE-5 Inhibition on Insulin Signaling in Skeletal Muscle.
Metabolic Syndrome
Primary: Insulin-stimulated AKT Phosphorylation — 0.065; -0.457 change in ratio
Phase 4 N=55 Pilot Study To Investigate The Association Between Acid Control And Heartburn Symptoms After Proton Pump Inhibitor Treatment
Heartburn
Primary: Number of Participants With Relief of 24 Hour Heartburn and Without Relief of 24 Hour Heartburn — 7; 10; 0; 9 participants
Phase 4 N=6 Riluzole in Fragile X Syndrome
Fragile X Syndrome
Primary: Clinical Global Impression-Improvement (CGI-I) — 3.5 units on a scale
Phase 4 N=211 Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany
Relapsing-Remitting Multiple Sclerosis
Primary: Number of Participants Who Utilized Symptomatic Therapy With Gastrointestinal-Related Events During the 12-Week Treatment Period: Modified Overall Gastrointestinal…
Phase 4 N=222 Study to Evaluate Efficacy/Safety of Combination Budesonide/Indacaterol vs Fluticasone/Salmeterol in Patients With COPD
Chronic Obstructive Pulmonary Disease
Primary: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (Non-inferiority Analysis). — 0.080; 0.019 Liters — p=0.004
Phase 4 N=38 Antimicrobial Agent for Reducing Bacteria in Aerosols and Oral Cavity
Dental Prophylaxis and Implant Surgery
Primary: Total Number of Detectable Plaque Bacteria Sampled 3 Days Post Implant Surgery — 7.63; 7.43 log(10) colony forming equivalents (CFE) — p=0.2965
Phase 4 N=87 Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study
Orthostatic; Hypotension, Neurogenic
Primary: Change in Orthostatic BP Drop — 11.1; 13.6; 8.9; 7.5 mmHg
Phase 4 N=44 Eovist vs. Dotarem Healthy Volunteer MRI
Transient Severe Arterial Phase Motion
Primary: Subject Breath Hold Capacity, as Measured by Number of Seconds a Subject Can Hold His/Her Breath — 28; 38; 35 seconds